flutide nasal 1 mg/ ml
glaxosmithkline as - flutikasonpropionat - nesedråper, suspensjon - 1 mg/ ml
flutivate 0.05 %
glaxosmithkline as - flutikasonpropionat - krem - 0.05 %
flutivate 0.005 %
glaxosmithkline as - flutikasonpropionat - salve - 0.005 %
seffalair spiromax
teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - legemidler for obstruktive sykdommer i luftveiene, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.
relvar ellipta 184 mikrog / 22 mikrog
2care4 aps - flutikasonfuroat / vilanteroltrifenatat - inhalasjonspulver, dosedispensert - 184 mikrog / 22 mikrog
flutiform 125 mikrog/ dose / 5 mikrog/ dose
2care4 - flutikasonpropionat / formoterolfumaratdihydrat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose / 5 mikrog/ dose
flutiform 125 mikrog/ dose / 5 mikrog/ dose
2care4 - flutikasonpropionat / formoterolfumaratdihydrat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose / 5 mikrog/ dose
flixotide 50 mikrog/ dose
orifarm as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose
flixotide 50 mikrog/ dose
orifarm as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose
airexar spiromax
teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - airexar spiromax er indisert for bruk hos voksne i alderen 18 år og eldre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesykdom (kols)airexar spiromax er indikert for symptomatisk behandling av pasienter med kols, med en fev1.